We Offer Worldwide Shipping
Login Wishlist

Linderone

$960

  • Brand : BIOFRON

  • Catalogue Number : BN-O1520

  • Specification : 98%(HPLC)

  • CAS number : 1782-79-2

  • Formula : C16H14O5

  • Molecular Weight : 286.3

  • PUBCHEM ID : 71307285

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1520

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

286.3

Appearance

Orange cryst.

Botanical Source

This product is isolated and purified from the roots of Lindera aggregata (Sims) Kosterm

Structure Type

Chalcones

Category

Standards;Natural Pytochemical;API

SMILES

CCCCCCCC=CCC(=O)C

Synonyms

2-[(2E)-1-Hydroxy-3-phenyl-2-propen-1-ylidene]-4,5-dimethoxy-4-cyclopentene-1,3-dione/Linderone/4-Cyclopentene-1,3-dione, 2-[(2E)-1-hydroxy-3-phenyl-2-propen-1-ylidene]-4,5-dimethoxy-

IUPAC Name

(E)-dodec-4-en-2-one

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

207.4±23.6 °C

Boiling Point

547.7±50.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C12H22O/c1-3-4-5-6-7-8-9-10-11-12(2)13/h9-10H,3-8,11H2,1-2H3/b10-9+

InChl Key

SNSAFZXASVXYNM-MDZDMXLPSA-N

WGK Germany

RID/ADR

HS Code Reference

2914190000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:1782-79-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29139962

Title

Farther Remarks on the Method of Treating the Remittent Fevers of the West Indies; with Observations on the Best Means of Preserving Health in Jamaica

Publish date

1782 Jan-Mar

PMID

29139963

Title

A Table of the Greatest, Least, and Mean Heights of the Thermometer and Barometer, and of the Fall of Rain in London in 1780

Publish date

1782 Jan-Mar;

PMID

10206293

Abstract

A range of measures have been proposed to enhance the provision of information to cancer patients and randomized controlled trials have demonstrated their impact on patient satisfaction and recall. The current study explored the practice and views of oncologists, surgeons and general practitioners (GPs) with regards to providing patients with consultation audiotapes and summary letters. In stage 1, 28 semi-structured interviews with doctors were conducted to provide qualitative data on which to base a questionnaire. In stage 2, 113 medical oncologists, 43 radiation oncologists, 55 surgeons and 108 GPs completed questionnaires. Only one-third of doctors had ever provided patients with a copy of the letter written to the oncologist or referring doctor, and one-quarter had provided a summary letter or tape. The majority of doctors were opposed to such measures; however, a substantial minority were in favour of providing a letter or tape under certain conditions. More surgeons and GPs (> two-thirds) were opposed to specialists providing a consultation audiotape than oncologists (one-third). Gender, years of experience and attitude to patient involvement in decision-making were predictive of doctors’ attitudes. The majority of doctors remain opposed to offering patients personalized information aids. However, practice and perspectives appear to be changing. © 1999 Cancer Research Campaign

KEYWORDS

Dr-pt communication, information provision, audiotapes, patient letters

Title

Audiotapes and letters to patients: the practice and views of oncologists, surgeons and general practitioners

Author

D McConnell,1 P N Butow,1 and M H N Tattersall2

Publish date

1999 Apr;


Description :

Empty ...